Compare BioNTech SE - ADR (BNTX) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs YieldMax NVDA Option Income Strategy ETF — how do they compare? BioNTech SE - ADR trades at $93.35 (market cap $23.31B), while YieldMax NVDA Option Income Strategy ETF trades at $13.06. Which is the better fit depends on your goals.
| BNTX | NVDY | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $119.34 | $17.96 |
52-Week Low | $83.89 | $11.58 |
Enterprise Value | $6.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
NVDY trades at $13.055, up 2.55% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividend income, with recent payouts ranging from $0.09 to $0.15 per share. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights the fund's strategy of selling NVIDIA call options to fund distributions, attracting income-focused investors.
The outlook for NVDY hinges on NVIDIA's volatility, which drives option premiums and dividends. However, investors sacrifice significant upside potential in NVIDIA's stock gains. Risks include underperformance versus direct NVIDIA ownership and fee drag. The ETF suits income seekers but may disappoint those seeking capital appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
